A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Abroad (travel likely)RecruitingPHASE1

Conditions

Systemic Lupus Erythematosus (SLE) · Sjogren's Syndrome (SS) · Systemic Sclerosis (SSc) · Inflammatory Myopathy · ANCA Associated Systemic Vasculitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Hu ji Xu, PhD) · xuhuji@smmu.edu.cn · 021-81886999

Study leads

Hu ji Xu
Principal Investigator
Shanghai Changzheng Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE) · Lupus Nephritis (LN) · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE1

Hefei, China

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Systemic Lupus Erythematosus · Inflammatory Myopathy · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE2

Beijing, China

US Zamto-cel Autoimmune Diseases

Lupus Nephritis · Systemic Lupus Erythematosus · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE1

Milwaukee, United States

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Autoimmune Diseases · Systemic Lupus Erythematosus · Systemic Sclerosis

Abroad (travel likely)RecruitingEARLY_PHASE1

Shanghai, China